恶性嗜铬细胞瘤的治疗
合集下载
相关主题
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Limited disease: curative intention
Extended disease: still to be considered in the first place for debulking and as palliative treatment
(Mundschenk et al. 2019)
Malignancy requires evidence of metastases at non-chromaffin sites distant from that of the primary tumor.
11.02.2021
4
Metastatic disease in pheochromocytoma may be present at the time of initial diagnosis or may only became evident after surgical removal of the primary tumor, usually within 5 years, but sometimes 16 or more years later.
Without treatment, the 5-year survival is generally less than 50%.
The course, however, can be highly variable with occasional patients living more than 20 years after diagnosis.
11.02.2021
6
Because there is currently no effective cure for malignant pheochromocytoma, most treatment are palliative, but in some cases may reduce tumor burden and prolong survival.
11.02.2021
13
Tumor size (mean ± SD) <2 cm 2.0-3.9 cm 4.0-5.9 cm 6.0-7.9 cm 8.0-9.9 cm ≥10 cm
11.02.2021
7
Once malignancy is diagnosed, therapy is generally directed at controlling blood pressure, but may also include tumor debulking.
11.02.2021
11.02.2021
11
Problem
When signs of regional involvement or distant disease are absent, there is currently no reliable preoperative diagnostic test that can differentiate between malignant and benign pheochromocytomas
Should pheochromocytoma size influence surgical approach?
11.02.2021
12
A comparison of 90 malignant and 60 benign pheochromocytomas
(Wen T. Shen et al.2019)
11.02.2021
5
Due to the rarity of the tumor, clinical studies about pheochromocytoma suffer from a fragmented nature and usually involve too small a number of cases to reach conclusive results.
11.02.2021
3
Malignant vs. Benign
Currently, there is no effective cure for malignant pheochromocytoma.
There are also no reliable histopathological methods for distinguishing benign from malignant tumors.
8
Alternative of Current Therapy
Surgery RadiophΒιβλιοθήκη Baidurmaceuticals Combined Chemotherapy Arterial Embolization
11.02.2021
9
Alternative of Current Therapy
Surgery Radiopharmaceuticals Combined Chemotherapy Arterial Embolization
11.02.2021
10
Primary surgical resection is the treatment of choice whenever possible
Introduction
The most frequent site of metastases is the skeleton
Additional sites are liver, retroperitoneum with lymph nodes, CNS, pleura, and kidney
Comparison of tumor size for benign pheochromocytomas and malignant pheochromocytomas with local disease only
Size does not reliably predict malignancy in pheochromocytomas with local disease only
Extended disease: still to be considered in the first place for debulking and as palliative treatment
(Mundschenk et al. 2019)
Malignancy requires evidence of metastases at non-chromaffin sites distant from that of the primary tumor.
11.02.2021
4
Metastatic disease in pheochromocytoma may be present at the time of initial diagnosis or may only became evident after surgical removal of the primary tumor, usually within 5 years, but sometimes 16 or more years later.
Without treatment, the 5-year survival is generally less than 50%.
The course, however, can be highly variable with occasional patients living more than 20 years after diagnosis.
11.02.2021
6
Because there is currently no effective cure for malignant pheochromocytoma, most treatment are palliative, but in some cases may reduce tumor burden and prolong survival.
11.02.2021
13
Tumor size (mean ± SD) <2 cm 2.0-3.9 cm 4.0-5.9 cm 6.0-7.9 cm 8.0-9.9 cm ≥10 cm
11.02.2021
7
Once malignancy is diagnosed, therapy is generally directed at controlling blood pressure, but may also include tumor debulking.
11.02.2021
11.02.2021
11
Problem
When signs of regional involvement or distant disease are absent, there is currently no reliable preoperative diagnostic test that can differentiate between malignant and benign pheochromocytomas
Should pheochromocytoma size influence surgical approach?
11.02.2021
12
A comparison of 90 malignant and 60 benign pheochromocytomas
(Wen T. Shen et al.2019)
11.02.2021
5
Due to the rarity of the tumor, clinical studies about pheochromocytoma suffer from a fragmented nature and usually involve too small a number of cases to reach conclusive results.
11.02.2021
3
Malignant vs. Benign
Currently, there is no effective cure for malignant pheochromocytoma.
There are also no reliable histopathological methods for distinguishing benign from malignant tumors.
8
Alternative of Current Therapy
Surgery RadiophΒιβλιοθήκη Baidurmaceuticals Combined Chemotherapy Arterial Embolization
11.02.2021
9
Alternative of Current Therapy
Surgery Radiopharmaceuticals Combined Chemotherapy Arterial Embolization
11.02.2021
10
Primary surgical resection is the treatment of choice whenever possible
Introduction
The most frequent site of metastases is the skeleton
Additional sites are liver, retroperitoneum with lymph nodes, CNS, pleura, and kidney
Comparison of tumor size for benign pheochromocytomas and malignant pheochromocytomas with local disease only
Size does not reliably predict malignancy in pheochromocytomas with local disease only